Reducing Risks and Delays in the Translation of Cell and Gene Therapy Innovations into Regulated Products

Katherine Tsokas; Richard McFarland; Carl Burke; Jessica L Lynch; Thomas Bollenbach; D Allen Callaway 2nd; Jay Siegel

doi:10.31478/201909d

Reducing Risks and Delays in the Translation of Cell and Gene Therapy Innovations into Regulated Products

NAM Perspect. 2019 Sep 30:2019:10.31478/201909d. doi: 10.31478/201909d. eCollection 2019.

Authors

Katherine Tsokas¹, Richard McFarland², Carl Burke³, Jessica L Lynch¹, Thomas Bollenbach², D Allen Callaway 2nd¹, Jay Siegel⁴

Affiliations

¹ Janssen Research and Development, LLC.
² Advanced Regenerative Manufacturing Institute.
³ Century Therapeutics.
⁴ Johnson & Johnson.

No abstract available

Publication types

Review

Grants and funding

The views expressed in this paper are those of the authors and not necessarily of the authors’ organizations, the National Academy of Medicine (NAM), or the National Academies of Sciences, Engineering, and Medicine (the National Academies). The paper is intended to help inform and stimulate discussion. It is not a report of the NAM or the National Academies.